Tubulis
Tubulis is a biotechnology company developing novel Antibody Drug Conjugates for solid tumours. Their two lead programs from their pipeline, TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4, are being evaluated in the clinic in high-need solid tumor indications.
Key Facts
- Sector
Life Sciences
- Country
Germany
- Fund
LSP 7
- Entry
2024
- Website
- https://tubulis.com/
- EQT Responsible Advisor
Christoph Broja
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.